Quarterly ResultAug 6, 2026, 07:38 AM
Climb Bio Q2 2026 Results; Cash Runway into H2 2028
AI Summary
Climb Bio, Inc. reported its financial results for the second quarter ended June 30, 2026, highlighting a strong cash position of $239.2 million, which is expected to fund operations into the second half of 2028. The company provided positive updates on its clinical pipeline, including the anticipated initiation of a CLYM116 Phase 2 trial in IgA nephropathy in Q3 2026 and expected data readouts for budoprutug programs in Q4 2026. This progress is supported by a recent $110 million private placement financing and the appointment of a new board member.
Key Highlights
- Cash, cash equivalents, and marketable securities were $239.2 million as of June 30, 2026.
- Company expects current cash balance to fund operations into the second half of 2028.
- R&D expenses were $9.7 million for Q2 2026, up from $6.6 million in Q2 2025.
- G&A expenses were $5.6 million for Q2 2026, up from $4.1 million in Q2 2025.
- CLYM116 Phase 2 trial in IgA nephropathy is anticipated to initiate dosing in Q3 2026.
- Budoprutug clinical programs expect data from pMN, ITP, and SLE studies in Q4 2026.
- Completed a private placement financing of approximately $110 million in April 2026.
- Appointed Breanna O'Reilly, Ph.D., to its Board of Directors in June 2026.
Price Impact
More from CLYM